BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.82 -0.37 (-4.52%) Market Cap: 1.62 Bil Enterprise Value: 2.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 75/100

Q1 2019 BioCryst Pharmaceuticals Inc Earnings Call Transcript

May 08, 2019 / 12:30PM GMT
Release Date Price: $7.81 (+1.56%)
Operator

Good day, ladies and gentlemen, and welcome to the BioCryst First Quarter 2019 Earnings Conference Call. (Operator Instructions)

As a reminder, this conference call is being recorded.

I will now like to introduce your host for today's conference, Mr. John Bluth, Senior Vice President of Investor Relations and Corporate Communications. Sir, you may begin.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - SVP of IR & Corporate Communications

Thank you, Ashley. Good morning and welcome to BioCryst First Quarter 2019 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; Chief Medical Officer, Dr. Bill Sheridan; CFO, Tom Staab; and Chief Commercial Officer, Lynne Powell. Following our remarks, we'll answer your questions.

Before we begin, I want to direct your attention to Slide 2, which discusses our use of forward-looking statements and potential risk factors regarding an investment in BioCryst. As

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot